NCT06409624

Brief Summary

The objective of this study is to examine the association between urinary and plasma biomarkers and change in estimated glomerular filtration rate (eGFR) among patients with pulmonary hypertension (PH).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
14mo left

Started May 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
May 2024Jul 2027

First Submitted

Initial submission to the registry

May 7, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 10, 2024

Completed
21 days until next milestone

Study Start

First participant enrolled

May 31, 2024

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

October 6, 2025

Status Verified

September 1, 2025

Enrollment Period

2.6 years

First QC Date

May 7, 2024

Last Update Submit

September 30, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Major adverse kidney events

    Number of patients experiencing ≥q of the individual outcomes of the composite outcome of eGFR decline ≥25%, initiation of dialysis, or all-cause mortality

    Baseline to 12 months

Secondary Outcomes (3)

  • Initiation of dialysis

    Baseline to 12 months

  • All-cause mortality

    Baseline to 12 months

  • Kidney function decline

    12 months

Other Outcomes (1)

  • Worsening PH

    Baseline to 12 months

Study Arms (2)

Pulmonary hypertension

Patients with diagnosed PH by right heart catheterization with or without PH-specific treatment

Other: No intervention is planned as part of the study

No pulmonary hypertension

Patients in whom PH was excluded by right heart catheterization

Other: No intervention is planned as part of the study

Interventions

No intervention is planned as part of the study

No pulmonary hypertensionPulmonary hypertension

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Inpatients admitted at University Hospital Giessen and Marburg, Campus Giessen with suspected or pre-diagnosed PH undergoing RHC

You may qualify if:

  • Inpatients aged ≥18 years
  • Undergoing right heart catheterization (RHC)

You may not qualify if:

  • Active tumor disease requiring targeted therapy
  • inflammatory or autoimmune disease with renal involvement requiring systemic immunosuppressive treatment
  • unexplained kidney function decline, defined as serum creatinine increase ≥0.5 mg/dL from baseline within the prior 7 days before RHC
  • Chronic kidney disease with eGFR \<20 ml/min/1.73 m2
  • non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload
  • if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before RHC
  • prediagnosed glomerulonephritis
  • polycystic kidney disease
  • postrenal obstruction
  • single kidney (functional or anatomical)
  • solid organ transplantation
  • anticipated life expectancy of \<12 months
  • likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant)
  • pregnancy or possibility of pregnancy in the next 12 months
  • inability to cooperate with respiratory maneuvers during renal Doppler
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Giessen and Marburg, Campus Giessen, Department of Internal Medicine II

Giessen, Hesse, 35392, Germany

Location

Related Publications (2)

  • Husain-Syed F, DiFrancesco MF, Deo R, Barr RG, Scialla JJ, Bluemke DA, Kronmal RA, Lima JAC, Praestgaard A, Tracy RP, Shlipak M, Kawut SM, Kim JS. Associations between eGFR and albuminuria with right ventricular measures: the MESA-Right Ventricle study. Clin Kidney J. 2023 Apr 21;16(9):1508-1520. doi: 10.1093/ckj/sfad096. eCollection 2023 Sep.

    PMID: 37664568BACKGROUND
  • Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6.

Biospecimen

Retention: SAMPLES WITH DNA

Urine and blood samples.

MeSH Terms

Conditions

Hypertension, PulmonaryRenal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular DiseasesRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Faeq Husain-Syed, MD

    University of Giessen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2024

First Posted

May 10, 2024

Study Start

May 31, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

July 1, 2027

Last Updated

October 6, 2025

Record last verified: 2025-09

Locations